66 reports of this reaction
2.2% of all BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE reports
#8 most reported adverse reaction
PNEUMONIA is the #8 most commonly reported adverse reaction for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, manufactured by Topco Associates LLC. There are 66 FDA adverse event reports linking BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE to PNEUMONIA. This represents approximately 2.2% of all 2,981 adverse event reports for this drug.
Patients taking BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PNEUMONIA is a less commonly reported adverse event for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, but still significant enough to appear in the safety profile.
In addition to pneumonia, the following adverse reactions have been reported for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE:
The following drugs have also been linked to pneumonia in FDA adverse event reports:
PNEUMONIA has been reported as an adverse event in 66 FDA reports for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PNEUMONIA accounts for approximately 2.2% of all adverse event reports for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, making it a notable side effect.
If you experience pneumonia while taking BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.